AEArvid Engström

Arvid Engström

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arvid Engström has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Björn Eliasson

    Department of Medicine Sahlgrenska University Hospital Gothenburg Sweden

    4 shared publications
  • Christian Jonasson

    Department of Public Health and Nursing, Faculty of Medicine and Health Science, HUNT Center for Molecular and Clinical Epidemiology NTNU—Norwegian University of Science and Technology Trondheim Norway

    4 shared publications
  • Kristian Hveem

    Department of Public Health and Nursing, Faculty of Medicine and Health Science, HUNT Center for Molecular and Clinical Epidemiology NTNU—Norwegian University of Science and Technology Trondheim Norway

    4 shared publications
  • Mads Melbye

    Department of Public Health and Nursing, Faculty of Medicine and Health Science, HUNT Center for Molecular and Clinical Epidemiology NTNU—Norwegian University of Science and Technology Trondheim Norway

    4 shared publications
  • Soffia Gudbjörnsdottir

    The Swedish National Diabetes Register Västra Götalandsregionen Gothenburg Sweden

    4 shared publications
  • Viktor Wintzell

    Clinical Epidemiology Division, Department of Medicine, Centre for Pharmacoepidemiology, Solna Karolinska Institutet Stockholm Sweden

    4 shared publications

Latest Publications

  • Open Access

    Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

    by Arvid Engström, Henrik Svanström, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Peter Ueda, et al.

    Aims: To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods: Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design. We included 158 961 new users of GLP ‐1 receptor agonists and 188 065 new users of sulfonylureas, aged 45 years or older. Liraglutide accounted for 72.9% of GLP ‐1 receptor agonist follow‐up time, followed by semaglutide (13.4%), exenatide (7.3%), dulaglutide (5.1%) and lixisenatide (1.3%). The primary outcome was incident Parkinson's disease, defined as a first‐ever diagnosis of Parkinson's disease ( ICD ‐10 G20 ) or Parkinson's disease dementia ( ICD ‐10 F02 .3) in national patient registers. Cox regression with propensity score weighting was used to estimate hazard ratios ( HRs ) and control for confounding. Results: Mean age was 65 years and 43% were female. Incidence rates for Parkinson's disease were 5.2 and 8.0 per 10 000 person‐years among GLP‐1 receptor agonist and sulfonylurea users, respectively (adjusted HR 0.81 [95% CI 0.68–0.96]). Results were consistent in a 2‐year lag‐time analysis (HR 0.84 [95% CI 0.70–1.02]) after excluding or censoring users of DPP‐4 inhibitors at cohort entry or during follow‐up (HR 0.74 [95% CI 0.60–0.93]) and in subgroup analyses by sex and age. Conclusion: In this large observational cohort study, use of GLP‐1 receptor agonists compared with sulfonylureas was associated with a lower risk of incident Parkinson's disease. These findings support a potential neuroprotective role of GLP‐1 receptor agonists, though replication in additional studies is needed.


  • Open Access

    Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study

    by Arvid Engström, Jonas Söderling, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Björn Pasternak, et al.

    Aims: To assess the comparative cardiovascular and renal effectiveness and safety of empagliflozin vs. dapagliflozin among patients with type 2 diabetes in routine clinical practice. Methods and results: Cohort study using data from nationwide registers in Sweden, Denmark, and Norway, from June 2014 to June 2021 included 141 065 new users of empagliflozin and 58 306 new users of dapagliflozin. Coprimary outcomes were major cardiovascular events (myocardial infarction, stroke, and cardiovascular death), heart failure (hospitalization or death because of heart failure) and serious renal events (renal replacement therapy, hospitalization for renal events, and death from renal causes). Secondary outcomes were the individual components of the primary outcomes, any cause death, and diabetic ketoacidosis. Use of empagliflozin vs. dapagliflozin was associated with similar risk of major cardiovascular events [adjusted incidence rate: 15.9 vs. 15.8 events per 1000 person-years; HR 1.02, (95% confidence interval 0.97–1.08)], heart failure [6.5 vs. 6.3 events per 1000 person-years; HR 1.05 (0.97–1.14)] and serious renal events [3.7 vs. 4.1 events per 1000 person-years; HR 0.97 (0.87–1.07)]. In secondary outcome analyses, the HRs for use of empagliflozin vs. dapagliflozin were 1.00 (0.93–1.07) for myocardial infarction, 1.03 (0.95–1.12) for stroke, 1.01 (0.92–1.13) for cardiovascular death, 1.06 (1.00–1.11) for any cause death, 0.77 (0.60–0.99) for renal replacement therapy, 1.20 (0.75–1.93) for renal death, 1.01 (0.90–1.12) for hospitalization for renal events and 1.12 (0.94–1.33) for diabetic ketoacidosis. Conclusion: Use of empagliflozin and dapagliflozin was associated with similar risk of cardiovascular and renal outcomes, mortality, and diabetic ketoacidosis.


  • Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study

    by Arvid Engström, Viktor Wintzell, Mads Melbye, Henrik Svanström, Björn Eliasson, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Anders Hviid, Peter Ueda, et al.

    Background and Aims: Clinical trials suggest that glucagon-like peptide-1 (GLP-1) receptor agonists may have beneficial effects on NAFLD but the impact on hard hepatic endpoints is unknown. We assessed the association between use of GLP-1 receptor agonists and risk of serious liver events in routine clinical practice. Approach and Results: Cohort study using data from nationwide registers in Sweden, Denmark and Norway, 2007-2020, including 91 479 initiators of GLP-1 receptor agonists and 244 004 initiators of the active comparator, dipeptidyl peptidase-4 (DPP4) inhibitors, without a history of chronic liver disease other than NAFLD/NASH. The primary outcome was serious liver events: a composite of incident compensated and decompensated cirrhosis and hepatocellular carcinoma. Secondary outcomes were the individual components of the primary outcome. Cox regression was used to estimate hazard ratios (HRs), using propensity score weighting to control for confounding. Users of GLP-1 receptor agonists had 608 serious liver events (adjusted incidence rate 16.9 events per 10 000 person-years), compared with 1770 events among users of DPP4 inhibitors (19.2 events per 10 000 person-years). The adjusted HR was 0.85 (95% CI 0.75 to 0.97) and the rate difference was -2.1 (-4.4 to 0.1) events per 10 000 person-years. In secondary outcome analyses the adjusted HR was 0.85 (0.75 to 0.97) for compensated and decompensated cirrhosis and 1.05 (0.80 to 1.39) for hepatocellular carcinoma. Conclusions: Use of GLP-1 receptor agonists was associated with a significantly reduced risk of serious liver events, driven by a reduction of compensated and decompensated cirrhosis. Export


  • Sodium–Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study

    by Arvid Engström, Viktor Wintzell, Mads Melbye, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Henrik Svanström, Björn Pasternak, et al.

    OBJECTIVE: To assess the association between use of sodium–glucose cotransporter 2 (SGLT2) inhibitors and the risk of new-onset atrial fibrillation (AF) in routine clinical practice. RESEARCH DESIGN AND METHODS: We used nationwide registers in Denmark, Norway, and Sweden from 2013 to 2018 in order to include patients without a history of AF who were newly prescribed an SGLT2 inhibitor or an active comparator (glucagon-like peptide 1 [GLP-1] receptor agonist). We performed a cohort study to assess new-onset AF in intention-to-treat analyses using Cox regression, adjusted for baseline covariates with propensity score weighting. RESULTS: We identified 79,343 new users of SGLT2 inhibitors (59.2% dapagliflozin, 40.0% empagliflozin, 0.8% canagliflozin, <0.1% ertugliflozin) and 57,613 new users of GLP-1 receptor agonists. Mean age of the study cohort was 61 years and 60% were men. The adjusted incidence rate of new-onset AF was 8.6 per 1,000 person-years for new users of SGLT2 inhibitors compared with 10.0 per 1,000 person-years for new users of GLP-1 receptor agonists. The adjusted hazard ratio (aHR) was 0.89 (95% CI 0.81–0.96), and the rate difference was 1.4 fewer events per 1,000 person-years (95% CI 0.6–2.1). Using an as-treated exposure definition, the aHR for new-onset AF was 0.87 (95% CI 0.76–0.99). No statistically significant heterogeneity of the aHRs was observed between subgroups of patients with and without a history of heart failure or major cardiovascular disease. CONCLUSIONS: In this cohort study using nationwide data from three countries, use of SGLT2 inhibitors, compared with GLP-1 receptor agonists, was associated with a modestly reduced risk of new-onset AF.